Nadofaragene firadenovec - Wikipedia Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
ADSTILADRIN | FDA STN: BLA 125700 Proper Name: nadofaragene firadenovec-vncg Tradename: ADSTILADRIN Manufacturer: Ferring Pharmaceuticals A S Indication: ADSTILADRIN is indicated for the treatment of adult patients
Ferring Highlights New Real-World Research with ADSTILADRIN . . . About ADSTILADRIN ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
Adstiladrin | European Medicines Agency (EMA) The active substance of Adstiladrin is nadofaragene firadenovec, an antineoplastic cell and gene therapy (ATC code: L01XL10) Nadofaragene firadenovec is a non-replicating, recombinant type 5 adenovirus vector-based gene therapy containing the human IFNα2b transgene
Nadofaragene firadenovec-vncg (urinary bladder route) Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
Ferring announces full availability of ADSTILADRIN . . . About ADSTILADRIN ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors